Endometriosis and tamoxifen therapy

M A Morgan, Morgan MA, Mark A. Morgan, Y Gincherman, Yevgeniy Gincherman, Gincherman Y, J J Mikuta, John J. Mikuta, Mikuta Jj
International Journal of Gynecology & Obstetrics · 1994 · vol. 45(1) , pp. 55–57 · doi:10.1016/0020-7292(94)90767-6 · PMID:7913061 · W2003242304
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This report details two premenopausal women who developed symptomatic endometriomas during tamoxifen therapy for breast cancer, suggesting a potential stimulatory effect on endometriosis that should be considered.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Tamoxifen is an estrogen antagonist/agonist often associated with antiestrogenic effects such as hot flushes and vaginal dryness in premenopausal women. Estrogenic side-effects, such as thromboembolic phenomena and endometrial proliferation has been reported in postmenopausal women. Paradoxically, tamoxifen has also been shown to be capable of increasing estrogen levels in premenopausal women. Since tamoxifen is being used more frequently in this group of women, potential adverse effects are only now being recognized. Two cases of premenopausal women who developed symptomatic endometriomas while on tamoxifen for breast cancer, are reported. Stimulation of endometriosis should be considered when pain and an ovarian mass develops in a woman on tamoxifen. The unique effects of tamoxifen in premenopausal women may contribute to this even in the presence of regular ovulation.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Breast Neoplasms Endometriosis Ovarian Diseases Tamoxifen Adult Breast Neoplasms Breast Neoplasms Combined Modality Therapy Endometriosis Female Humans Ovarian Diseases Premenopause Tamoxifen Tamoxifen

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (9)

Cited by (10)

Source provenance

europepmc
last seen: 2026-09-21T06:08:07.822426+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:29.222973+00:00
License: CC0 · commercial use OK